Menu
Share this

Real-world Outcomes

In the past 15 years, PPD has designed, conducted, analyzed and reported/managed more than 1,000 studies across all areas of medical affairs and real-world outcomes. Our global services span the product life cycle.

Strong, Comprehensive Medical Affairs and Real-world Outcomes Research Experience

R&D spend for medical affairs research is increasing, indicating the importance of having a better understanding of and evidence for how products will perform in a real-world setting to determine their true market value. PPD can collaborate in the design, implementation, analysis and reporting of scientifically robust and innovative research, providing real-world evidence of a product's safety, effectiveness and economic value. PPD's real-world outcomes capabilities include:

  • Epidemiology
  • Health economics and outcomes research
  • Observational research
  • Patient, product and disease registries
  • Post-approval safety studies
  • Pragmatic Phase IV trials
  • Patient-reported outcomes
  • Expanded access and compassionate use programs
  • Extended access programs
  • Interventional studies

Health Economics

Health economic research is conducted to generate evidence of the economic benefit or impact of a health technology in a particular setting to optimize patient access to health technologies. This optimization is achieved by demonstrating to payers and health technology assessment agencies the economic value of a new product, resulting in optimal formulary placement with a minimum of utilization restrictions.

The types of economic analyses that might be conducted on a new health technology may be any combination of the following:

  • Budget impact analysis
  • Cost of illness study
  • Cost-efficacy/effectiveness analysis
  • Cost-minimization analysis
  • Cost-utility analysis

HealthCore Alliance

PPD and HealthCore have established a health services and real-world outcomes research partnership. Our clients can now benefit from PPD’s clinical trial design, health economics and outcomes research and medical affairs research services in addition to HealthCore’s strengths in innovative real-world research designs and robust research-enabled electronic health care data environment. This partnership generates evidence that will more quickly demonstrate how products will perform and benefit patients in the real world, while covering product research in pre- and post-approval settings. Together, we are setting new standards for quality, cost and speed of real-world evidence research. The information generated can facilitate decisions and speed products to market.

Patient-reported Outcomes

Patient-reported outcomes are a subset of a broader category of assessments — clinical outcomes assessments (COA) — that may be carried out to understand the broad impact of a new health technology.

The four types of COAs are patient-reported outcome (PRO) measures, clinician-reported outcome (ClinRO) measures, observer-reported outcome (ObsRO) measures and performance outcome (PerfO) measures.

A PRO is a measurement based on a report that comes from the patient (i.e., study subject) about the status of a patient’s health condition without amendment or interpretation of the patient’s report by a clinician or anyone else.

Typical PROs that are generated during a product development program include:

  • Disease-specific, health-related quality of life
  • General health-related quality of life
  • Health utilities measurements
  • Patient preference and/or satisfaction
  • Symptom scores

The PRO research plan for a new product may be of prime strategic importance to its commercial success, because they can serve as an important differentiator over a competitor. A PRO strategy should be planned and implemented in the earliest stages of product development.

Epidemiology

PPD takes a collaborative, customized approach to developing epidemiologic data, information and knowledge that allow our clients to:

  • Make more informed decisions with greater control of their data
  • Demonstrate their product’s safety, effectiveness and quality with a strong evidence basis
  • Gain the necessary insights to optimize treatment advice and realize their product’s greatest value

The science includes objective clinical outcomes as well as provider- and patient-reported outcomes. While public health experts have traditionally focused on post-approval, population-oriented safety and effectiveness, the biopharmaceutical industry recognizes the value of leveraging the science early in the product development process.

PPD’s epidemiology and health outcomes experts are:

  • Engaged in product safety and health outcomes across the product life cycle and risk management continuum
  • Focused on addressing safety and health outcomes holistically and contributing to a product’s comprehensive benefit-risk profile
  • Committed to understanding each client’s unique needs and offering flexible, creative and fully customized study solutions

Unlike interventional studies, which are based on a single design, epidemiologic (observational) studies vary in design and are unique in execution. Because companies are often unsure how to answer critical epidemiologic questions, PPD works closely with clients to first understand their challenges and identify the optimal approach. PPD’s epidemiologists have consulted on the design and successful execution of many types of studies. A partial listing of these studies includes:

  • Case-control studies
  • Chart reviews
  • Comparative effectiveness research (CER)
  • Cross-sectional studies
  • Drug (product) utilization studies
  • Focus group and key informant interviews (qualitative data)
  • Observational cohort studies
  • Post-authorization safety studies (PASS)
  • Practice pattern studies
  • Registries (disease, event, product)
  • Risk evaluation and mitigation strategy (REMS) assessments
  • Safety (signal) issue detection and evaluation
  • Secondary database studies
  • Surveillance studies
  • Survey research
  • Systematic reviews and meta-analyses

Getting Real: Partnering for Clinical and Real-world Evidence Studies

At the earliest stages of drug development, real-world evidence can be generated on the disease, its natural history, treatment patterns and treatment outcomes. Read more in a Contract Pharma article by Michael Pollock, a leading expert on real-world outcomes.

Contact Us

PPD Completes Evidera Acquisition, Establishes Global Leader in Real-World Research

Evidera to join PPD

PPD acquires Evidera, establishing the global leader in real-world research.

Medical Affairs Brochure

PPD Medical Affairs Brochure

Commercialize and access products effectively with PPD’s medical affairs and real-world outcomes services.

Contact Site Map Legal Notices Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.

Google+